1. Sun Pharmaceutical Industries to buy remaining stake in Taro Pharmaceutical Industries for $347.8 million.
2. US fund Platinum wants to buy India based Inventia Health at a valuation of INR 2,500 crore (~$300 million).
3. Jubilant Pharmova sells stake in Sofie Biosciences for $139.4 million.
4. Dr. Reddy's acquires 6.5 per cent stake in Israeli biotech company Edity.
5. Sun Pharma & Bayer collaborate to market new renal therapy.
6. Dr. Reddy's acquires MenoLabs' women health brands in US.
7. Laurus Labs has entered into Joint Venture with Slovenia-based drug manufacturer Krka.
8. Glenmark Specialty SA signs license agreement with Jiangsu Alphamab, 3D Medicine for Envafolimab.
9. Glenmark partners with Pfizer to launch Abrocitinib in India.
10. Merck in talks to buy Harpoon Therapeutics for around $700 Million.
11. Bora Pharmaceuticals to buy Upsher-Smith for $210 million.
12. Sandoz to buy eye drug Cimerli in $170 million deal.
13. Novartis signs gene therapy deal with Voyager for $100 Million upfront.
14. Qlucore has agreed a two-year license with Boehringer Ingelheim worth approximately SEK 1.67 million.
15. Biocytogen Pharmaceuticals out-licenses ADC to Radiance Biopharma.

1. Happy with our services, two (02) clients awarded contract extension to Aagami.
2. Aagami has completed a super busy, fruitful JPM week and Biotech Showcase 2024 (January 8–10, 2024, San Francisco) with 50+ one-on-one strategic partnering meetings for Aagami and its clients. 
3. Aagami to attend DCAT week 2024 in New York City (March 18-21). Let us meet if you are there too. Kindly inform, please. 
4. Aagami to attend BIO International Convention 2024 in San Diego. Registration completed. Meetings calendar to open shortly.
5. Aagami is celebrating its 21^st Anniversary and shall offer special pricing for new assignments until March 31^st, 2024.

For Partnering/Licensing/ Co-development:

1. Licensing available for Japan: Market-ready Denosumab biosimilar to PROLIA^® & XGEVA^®. Other high potential Biosimilars are also available for multiple regions.
2. Partnering/Licensing: A small molecule NSAID combination for Migraine using 505(b)(2).
3. Seeking Acquisition /JV – Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial of 30 patients ongoing in AU).
4. Seeking Licensing/Co-development:  A phase 2 (USA) stage Tizanidine patch using proprietary ILTS technology for management of spasticity from a Japanese client.

For Acquisition:

1. Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP, etc.- for Next-generation biologics and substantial returns.
2. IP/Asset sale: A small molecule NSAID combination for Migraine using 505(b)(2)
3. Asset sale –US client’s Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial of 30 patients ongoing in AU).

Seeking Investment:

1. Seeking US$15 million: Nose-to-brain technology development company targeting orphan diseases such as FrontoTemporal Dementia (FTD), Alzheimer’s disease, Dementia with Lewy Bodies, and Parkinson's disease.
2. Seeking US$5 million: Integrated Autoimmune company leading the Next Healthcare Revolution by Uncovering the drivers of autoimmune diseases to advance therapeutic assets.
3. Seeking US$5 million: A single (monovalent) vaccine for Targeting Salmonella, ETEC / E. coli, Campylobacter, Shigella. Fulfills an unmet need for treating Bacterial Dysentery.
4. Seeking US$5 million: Midwest US-based Pharma with Phase 2 stage First-in-Class Non-Opioid Analgesic NCE for Pain Relief.

Hope you found the content useful. We welcome your feedback and queries.